Amycretin: Novo Nordisk's Next-Generation Weight Loss Drug

Why amycretin matters

Current GLP-1 drugs work on one main pathway. Amycretin hits two at once: the GLP-1 receptor (the same target as semaglutide) plus the amylin receptor — a separate satiety hormone pathway that pharmaceutical researchers consider the next frontier after GLP-1/GIP combinations. Two complementary appetite-suppression mechanisms in one molecule is why analysts project it could become the strongest weight loss drug yet developed.

What the early data shows

• Oral amycretin: ~13% weight loss at 12 weeks in early data — remarkable for a pill that early.
• Injectable amycretin: up to ~22% at 36 weeks — potentially matching or exceeding tirzepatide (~21% over 72 weeks) in a shorter window.
• Safety profile: GI side effects (nausea, vomiting) similar to existing GLP-1s in early cohorts — no new red-flag signals yet.

Important caveat: these are early-phase, smaller trials. Phase 3 results routinely land lower than Phase 1/2 enthusiasm. For comparison on drugs available now, see semaglutide vs tirzepatide and our GLP-1 pipeline 2026 guide.

How it compares to what exists

Amycretin vs CagriSema

Both hit amylin + GLP-1, but differently: CagriSema is a co-formulation of cagrilintide (amylin analog) + semaglutide — two molecules in one pen. Amycretin is a single engineered molecule doing both jobs. Single molecules are generally easier to manufacture, dose, and potentially to make orally available — which is why amycretin getting a pill version matters so much.

What to do while waiting

Pipeline drugs are exciting, but the metabolic benefit of losing weight now compounds — waiting two-plus years for a better molecule costs real health time. The rational move: start on an available GLP-1, build the protein-and-training habits that protect muscle, and re-evaluate when amycretin (or Foundayo/orforglipron, coming sooner) actually launches. See our Foundayo guide for the nearest-term new option.

Frequently asked questions

What is amycretin?

Amycretin is Novo Nordisk's next-generation weight loss drug — a single molecule that activates both the GLP-1 receptor (like semaglutide) and the amylin receptor. Amylin is a hormone that controls satiety through a different brain pathway than GLP-1, so combining them may produce greater weight loss than GLP-1 alone.

How much weight does amycretin help you lose?

Early trial data showed roughly 13% weight loss over 12 weeks with the oral version and up to ~22% over 36 weeks with the subcutaneous version. These are early-phase results — larger Phase 3 trials will give the definitive numbers, but the trajectory suggests amycretin could match or exceed tirzepatide's ~21%.

Is amycretin a pill or injection?

Both are in development. Novo is testing a once-daily oral tablet and a once-weekly subcutaneous injection. The injection showed the stronger early results (~22%), but an effective daily pill would be a major option for needle-averse patients.

When will amycretin be available?

No approval date yet. Novo advanced amycretin into later-stage development based on early results, but Phase 3 trials take years — realistic availability is likely 2028 or later, assuming trials succeed. It is not currently prescribable in any form.

What can I take now while waiting for amycretin?

FDA-approved GLP-1s are available today: Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide). Compounded semaglutide via licensed telehealth starts at $119/month — far below brand retail.

Bottom line

Amycretin is the most interesting molecule in Novo's pipeline — dual amylin + GLP-1 with early numbers rivaling the best injectable on the market, plus a working pill. But it is years away. The drugs that exist today already deliver 15-21% weight loss; the smart play is starting now from $119/month and upgrading when the pipeline arrives.